![VJHemOnc Podcast](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2.jpg)
58.4K
Downloads
272
Episodes
The Video Journal of Hematology and Hematological Oncology (VJHemOnc) podcast covers the latest hematological oncology and hematology news from international experts – from leukemias, lymphomas, MDS and MPNs, to sickle cell, aplastic anemia and rare diseases. Made for healthcare professionals and researchers, we are a global, independent, open-access platform. Listen to the latest news, including cutting-edge trial updates, controversies and opinion. If you enjoy the podcast, please leave us a rating and review! For more news visit www.vjhemonc.com
Episodes
![The AML sessions: venetoclax-based regimens](https://pbcdn1.podbean.com/imglogo/image-logo/8189927/VJH_Thumbnail_1400b48w2_300x300.jpg)
Thursday Nov 12, 2020
The AML sessions: venetoclax-based regimens
Thursday Nov 12, 2020
Thursday Nov 12, 2020
The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms of resistance and future directions of venetoclax in combination with hypomethylating agents and IDH inhibitors have been evaluated and data presented at EHA 2020, as well as SOHO 2020 has shown promising results in AML.
In this podcast, Naval Daver, of The University of Texas MD Anderson Cancer Center, Houston, TX, leads an exciting discussion alongside Courtney DiNardo and Marina Konopleva, also from The University of Texas MD Anderson Cancer Center, as well as Andrew Wei of Monash University, Melbourne, Australia, on the latest updates in the use of venetoclax-based regimens for the treatment of AML.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.